BioSense Global, LLC serves as a conduit for foreign-based investors and biotech/biopharma companies eager to capitalize on the vast opportunities in the global market. Through research and development and venture capital investment, BioSense acts as a pathfinder, bridging Eastern and Western innovations and investment opportunities.
The Chinese biopharmaceutical market is emerging on the global stage as a virtually untapped industry. The increasingly wealthy and aging population of China, representing the second largest market in the world, has historically been underserved and new treatments are in high demand. The Chinese government recognizes biotechnology a driver for economic growth and encourages this sector’s development within its border, elevating China as a world leader in product innovation and development.
Research & DevelopmentMore on Research & Development
Although the demand for biopharmaceutical products in China is tremendous, research and development has lagged. BioSense’s objective is to open doors for foreign-based companies to the biopharmaceutical arena for research, development, and distribution opportunities. BioSense has an experienced team on the ground, ready to assist its clients and partners in both startup and product development to maximize investment returns.
PartnershipsMore on Partnerships
We believe in the critical value of win-win partnerships and are continually seeking new industry partners. Our current business partners include: Neovacs S.A. PrimeVax Immuno-Onocology, Inc.Curtana Pharmaceuticals Locus Biosciences Beijing CoSci Med-Tech Co.,LtdTorreya Partners LLCQingyuan Nimbus LLC
InvestmentMore on Investment
As a venture capital investment fund with an emphasis on the research and development of novel drug discovery and medical devices, BioSense brings together investors from both the East and West to fund development wherever opportunities present themselves. BioSense also serves as an operational partner in the execution of research and development and eventual production.